SAREPTA THERAPEUTICS INC (1SRPT.MI) Stock Price, Forecast & Analysis
BIT:1SRPT • US8036071004
1SRPT.MI Key Statistics, Chart & Performance
The current stock price of 1SRPT.MI is 18.84 EUR.
1SRPT.MI Technical Analysis
ChartMill assigns a technical rating of 3 / 10 to 1SRPT.MI.
1SRPT.MI Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to 1SRPT.MI. Both the profitability and financial health of 1SRPT.MI have multiple concerns.
1SRPT.MI Financial Highlights
Over the last trailing twelve months 1SRPT.MI reported a non-GAAP Earnings per Share(EPS) of -1.03. The EPS decreased by -197.6% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -7.77% | ||
| ROE | -20.57% | ||
| Debt/Equity | 0.78 |
1SRPT.MI Forecast & Estimates
33 analysts have analysed 1SRPT.MI and the average price target is 25.78 EUR. This implies a price increase of 36.86% is expected in the next year compared to the current price of 18.84.
For the next year, analysts expect an EPS growth of -342.71% and a revenue growth 14.25% for 1SRPT.MI
1SRPT.MI Ownership
1SRPT.MI Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ARGX | ARGENX SE | 27.82 | 43.368B | ||
| 1AE | ARGENX SE | 27.92 | 43.306B | ||
| 22UA | BIONTECH SE-ADR | N/A | 22.074B | ||
| ABVX | ABIVAX SA | N/A | 7.703B | ||
| 2X1 | ABIVAX SA | N/A | 7.695B | ||
| GXE | GALAPAGOS NV | N/A | 1.887B | ||
| GLPG | GALAPAGOS NV | N/A | 1.871B | ||
| IVA | INVENTIVA SA | N/A | 984.579M | ||
| 6IV | INVENTIVA SA | N/A | 978.821M | ||
| NANO | NANOBIOTIX | N/A | 972.597M |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Euronext Milan Exchange | Find stocks with similar TA and Setup ratings on the European exchanges | Find stocks with similar Fundamental rating on the European exchanges | Find the competitors with the best technical ratings on the European exchanges | Find the competitors with the best fundamentals on the European exchanges | Find the competitors with the best valuation on the European exchanges | Find the competitors with the best dividend on the European exchanges | Find the competitors with the best analyst ratings on the European exchanges
About 1SRPT.MI
Company Profile
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,372 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Company Info
SAREPTA THERAPEUTICS INC
215 First Street, Suite 415
Cambridge MASSACHUSETTS US
Employees: 1372
Phone: 16172744000
SAREPTA THERAPEUTICS INC / 1SRPT.MI FAQ
What does 1SRPT do?
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company is headquartered in Cambridge, Massachusetts and currently employs 1,372 full-time employees. The firm is focused on helping patients through the discovery and development of ribonucleic acid (RNA)-targeted therapeutics, gene therapy and other genetic therapeutic modalities for the treatment of rare diseases. The company has developed multiple approved products for the treatment of Duchenne muscular dystrophy (Duchenne) and is developing potential therapeutic candidates for a range of diseases and disorders, including Duchenne, Limb-girdle muscular dystrophies (LGMDs) and other neuromuscular and central nervous system (CNS) related disorders. The firm has developed and commercialized four approved products for the treatment of Duchenne: EXONDYS 51 (eteplirsen), Injection (EXONDYS 51), VYONDYS 53 (golodirsen) Injection (VYONDYS 53), AMONDYS 45 (casimersen) Injection (AMONDYS 45), and ELEVIDYS. Its pipeline includes over 40 programs at various stages of discovery, pre-clinical and clinical development.
Can you provide the latest stock price for SAREPTA THERAPEUTICS INC?
The current stock price of 1SRPT.MI is 18.84 EUR. The price increased by 6.02% in the last trading session.
Does SAREPTA THERAPEUTICS INC pay dividends?
1SRPT.MI does not pay a dividend.
What is the ChartMill rating of SAREPTA THERAPEUTICS INC stock?
1SRPT.MI has a ChartMill Technical rating of 3 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
On which exchange is 1SRPT.MI stock listed?
1SRPT.MI stock is listed on the Euronext Milan exchange.
What do analysts say about SAREPTA THERAPEUTICS INC (1SRPT.MI) stock?
33 analysts have analysed 1SRPT.MI and the average price target is 25.78 EUR. This implies a price increase of 36.86% is expected in the next year compared to the current price of 18.84.
What is SAREPTA THERAPEUTICS INC worth?
SAREPTA THERAPEUTICS INC (1SRPT.MI) has a market capitalization of 1.97B EUR. This makes 1SRPT.MI a Small Cap stock.